Bulletin du cancer最新文献_第3页

[Pre-, per- and post-allogeneic haematopoietic stem cell transplant rehabilitation (SFGM-TC)]. [异体造血干细胞移植前、移植前和移植后的康复（Atelier SFGM-TC）]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-07-08 DOI: 10.1016/j.bulcan.2024.05.006

Virgile Pinelli, Laure Christophe, Nathalie Cheron, Sarah Morin, Lila Gilis, Candy Heuze, Dominique Clerc-Renaud, Laurence Morotti, Benoit Vilhet, Sandra Bissardon, Leonardo Magro

{"title":"[Pre-, per- and post-allogeneic haematopoietic stem cell transplant rehabilitation (SFGM-TC)].","authors":"Virgile Pinelli, Laure Christophe, Nathalie Cheron, Sarah Morin, Lila Gilis, Candy Heuze, Dominique Clerc-Renaud, Laurence Morotti, Benoit Vilhet, Sandra Bissardon, Leonardo Magro","doi":"10.1016/j.bulcan.2024.05.006","DOIUrl":"10.1016/j.bulcan.2024.05.006","url":null,"abstract":"Allogeneic transplantation of haematopoietic stem cells is still the only curative treatment for certain haematological malignancies. This treatment can be responsible for a number of side-effects, leading to multiple and interdependent physical and psychological deficiencies that affect patients' quality of life and social participation, and can be experienced as a handicap, sometimes for several years after the transplant. For several years now, the integration of post-transplant rehabilitation pathways has been becoming more widespread, and initiatives to provide multidisciplinary care at an increasingly early stage are being studied. The aim of this early management is to improve the patient's overall functional state before, during and after the transplant, in order to limit the impact of the treatment and ensure the quickest possible return to a life that is as satisfying as possible. The international literature and the experiments carried out throughout the French-speaking world describe heterogeneous practices. Based on this literature and experience, the aim of this study is to issue homogenous recommendations for good clinical practice and to identify areas for further research into pre-transplant, per-transplant and post-transplant rehabilitation of haematopoietic stem cells.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"S2-S9"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141565575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Preventive and therapeutic strategies for relapse after hematopoietic stem cell transplant for pediatric AML (SFGM-TC)]. [小儿急性髓细胞性白血病造血干细胞移植后复发的预防和治疗策略（SFGM-TC）]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-06-25 DOI: 10.1016/j.bulcan.2024.02.006

Cécile Renard, Alizee Corbel, Catherine Paillard, Cécile Pochon, Pascale Schneider, Nicolas Simon, Nimrod Buchbinder, Mony Fahd, Ibrahim Yakoub-Agha, Charlotte Calvo

{"title":"[Preventive and therapeutic strategies for relapse after hematopoietic stem cell transplant for pediatric AML (SFGM-TC)].","authors":"Cécile Renard, Alizee Corbel, Catherine Paillard, Cécile Pochon, Pascale Schneider, Nicolas Simon, Nimrod Buchbinder, Mony Fahd, Ibrahim Yakoub-Agha, Charlotte Calvo","doi":"10.1016/j.bulcan.2024.02.006","DOIUrl":"10.1016/j.bulcan.2024.02.006","url":null,"abstract":"Treatment of pediatric high-risk acute myeloid leukemia (AML), defined either on molecular or cytogenetic features, relies on bone marrow transplant after cytologic remission. However, relapse remains the first post-transplant cause of mortality. In this 13th session of practice harmonization of the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC), our group worked on recommendations regarding the management of post-transplant relapse in AML pediatric patients based on international literature, national survey and expert opinion. Overall, immunomodulation strategy relying on both measurable residual disease (MRD) and chimerism evaluation should be used for high-risk AML. In very high-risk (VHR) AML with a 5-year overall survival ≤30 %, a post-transplant maintenance should be proposed using either hypomethylating agents, combined with DLI whenever possible, or FLT3 tyrosine kinase inhibitors if this target is present on leukemia cells. In the pre-emptive or early relapse settings (< 6 months post-transplant), treatments combining DLI, Azacytidine and Venetoclax should be considered. Access to phase I/II trails for targeted therapies (menin, IDH or JAK inhibitors) should be discussed in each patient according to the underlying molecular abnormalities of the disease.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"S135-S145"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Triple negative breast cancer: Current status and perspectives]. [三阴性乳腺癌：现状与展望]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-11-06 DOI: 10.1016/j.bulcan.2024.09.002

Fanny Le Du, Emilie Moati, Pauline Vaflard, Caroline Bailleux, Jean-Yves Pierga, Véronique Dieras

{"title":"[Triple negative breast cancer: Current status and perspectives].","authors":"Fanny Le Du, Emilie Moati, Pauline Vaflard, Caroline Bailleux, Jean-Yves Pierga, Véronique Dieras","doi":"10.1016/j.bulcan.2024.09.002","DOIUrl":"10.1016/j.bulcan.2024.09.002","url":null,"abstract":"Triple negative breast cancer (TNBC) is defined by the absence of expression of estrogen and progesterone receptors, as well as the absence of overexpression of HER2. Accounting for 10 to 15% of breast cancers, it remains characterized by an aggressive phenotype with an increased risk of early recurrence and overall survival less favorable compared to other subtypes. The challenges in management and therapeutic evolution are likely related to the demonstrated high biological heterogeneity of this subtype. Regarding therapeutic management, chemotherapy remains the cornerstone of TNBC treatment. In the early stage, the neoadjuvant strategy is the standard, allowing adaptation of the adjuvant sequence depending on whether a complete histological response is achieved or not. Dose-dense chemotherapy regimens and the addition of carboplatin have been associated with an improvement in these response rates. Furthermore, immunotherapy, particularly pembrolizumab, has shown significant benefits in terms of recurrence-free survival. In the metastatic setting, the role of theranostic markers is now established, allowing access to immunotherapy (pembrolizumab if CPS PD-L1>10%) or PARP inhibitors (in case of constitutional BRCA mutation). Antibody-drug conjugates are gradually moving up the lines, offering promising prospects in these complex situations. In conclusion, despite recent progress, TNBC remains a major clinical challenge. A better understanding of its biology and a personalized therapeutic approach are essential to improve clinical outcomes for patients with this aggressive form of breast cancer.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"82-99"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Setting up haploidentical hematopoietic cell transplantation in low- and middle-income countries: The Recommendations of the Francophone Society of Bone Marrow and Cellular Therapy (SFGM-TC)]. [在中低收入国家开展单倍体造血细胞移植：法语国家骨髓和细胞治疗协会（SFGM-TC）的建议]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-10-18 DOI: 10.1016/j.bulcan.2024.09.001

Fati Hamzy, Patrice Chevallier, Bénédicte Bruno, Valérie Coiteux, Maria El Kababri, Ahmad Ibrahim, Anas Oudrhiri, Ibrahim Yakoub-Agha, Mohamed-Amine Bekadja

{"title":"[Setting up haploidentical hematopoietic cell transplantation in low- and middle-income countries: The Recommendations of the Francophone Society of Bone Marrow and Cellular Therapy (SFGM-TC)].","authors":"Fati Hamzy, Patrice Chevallier, Bénédicte Bruno, Valérie Coiteux, Maria El Kababri, Ahmad Ibrahim, Anas Oudrhiri, Ibrahim Yakoub-Agha, Mohamed-Amine Bekadja","doi":"10.1016/j.bulcan.2024.09.001","DOIUrl":"10.1016/j.bulcan.2024.09.001","url":null,"abstract":"Nowadays, haploidentical hematopoietic cell transplantation (haplo-HCT) has been routinely used worldwide. However, this procedure is still rarely proposed in low- or middle-income countries. During the 13th annual harmonization workshops of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), a designated working group has proposed recommendations on how to set up such a transplantation in these countries. This was based on a review of the literature and expert-opinion as well as the previously published workshop on haplo-HCT of SFGM-TC (2016). Haploidentical donors appear to be a first alternative to HLA-matched siblings since the access to unrelated donor international registries are limited for several countries. While the procedure has the advantage of immediate access to several potential donors and of low cost, Haplo-HCT should be performed only in centers with a good experience of HLA-matched related transplantation (>10/year). In the absence of an HLA-matched related donor, haplo-HCT should be offered to all patients who are candidate for allo-HCT. Transplantation modalities should follow the conventional procedures with post-transplant cyclophosphamide as GVHD prophylaxis. Conditioning can be myeloablative or not according to each case. Our recommendations are intended to be general in scope and applicable to the majority of allo-HCT centers in these countries. An evaluation at regular basis is needed to assess the feasibility and to improve results.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"S146-S156"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142483051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A 2024 inventory in oncology news]. [肿瘤学新闻 2024 年盘点]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-12-16 DOI: 10.1016/j.bulcan.2024.12.001

Stéphane Vignot, Audrey Bellesoeur, Carole Bouleuc, Romain Cohen, Baudouin Courtier, Carolyne Crozier, Alexandre De Nonneville, Frédéric Delom, Serge Evrard, Nelly Firmin, Virginie Gandemer, Mohamed Khettab, Nicolas Magné, Daniel Orbach, Isabelle Pellier, Manuel Rodrigues, Marie Wislez, Jacques-Olivier Bay

引用次数: 0

[Letter to young oncologists of the 21st century]. [致 21 世纪年轻肿瘤学家的一封信]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-12-18 DOI: 10.1016/j.bulcan.2024.12.006

Thierry Philip

引用次数: 0

[Precision medicine in oncology: A reality… without equity]. [肿瘤学中的精准医学：没有公平的现实......]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-10-09 DOI: 10.1016/j.bulcan.2024.08.008

Frédérique Pénault-Llorca, Clarisse Audigier-Valette, Pierre-Jean Lamy, Dominique Stoppa Lyonnet, Philippe Camparo, Sophie Beaupère, Xavier Troussard, Laure Gueroult Accolas, Gérard Raymond, Alexandre Auday, Jean-Yves Blay, François Sarkozy

{"title":"[Precision medicine in oncology: A reality… without equity].","authors":"Frédérique Pénault-Llorca, Clarisse Audigier-Valette, Pierre-Jean Lamy, Dominique Stoppa Lyonnet, Philippe Camparo, Sophie Beaupère, Xavier Troussard, Laure Gueroult Accolas, Gérard Raymond, Alexandre Auday, Jean-Yves Blay, François Sarkozy","doi":"10.1016/j.bulcan.2024.08.008","DOIUrl":"10.1016/j.bulcan.2024.08.008","url":null,"abstract":"The prognostic of certain cancers improved significantly in recent years thanks not only to the launch of innovative treatments but also to progress made in the diagnostic field. Thus, next-generation sequencing (NGS) became paramount to help characterizing tumors and selecting the most pertinent treatments. The survey conducted by a multi stakeholder committee, at the end of 2022, with 103 actors of the management of cancer patients (public and private centers, labs, prescribers, biologists, pathologists, direction) confirmed the heterogeneity of use of NGS tests across France due to, mainly, the lack of systematic reimbursement of related costs. Référentiel des actes innovants hors nomenclature de biologie (RIHN) covers, in a delayed and partial way, only half of costs engaged by centers. Only those with a critical mass of patients or with a sufficient funding capacity can guarantee an access to large panels. Postponing the initiation of a required treatment represents a risk of loss of opportunity for patients who cannot benefit of this technology. NGS large panels tests, an efficiency lever for cancer treatment, must be part of the care toolbox. Those with a demonstration of value created should nowadays be fully reimbursed by collectivity after HAS' evaluation, for a fair access throughout the territory. Precision diagnostic can open the way to a more personalized and efficient medicine.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"15-18"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Acquired severe aplastic anemia in emerging countries: Management from allogeneic hematopoietic cell transplantation indication until post-transplant follow-up SFGM-TC]. [新兴国家的后天性重型再生障碍性贫血：从异体造血细胞移植适应症到移植后随访的管理 SFGM-TC]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-09-02 DOI: 10.1016/j.bulcan.2024.07.008

Nabil Yafour, Mohamed Amine Bekadja, Ibtissam El Bejjaj, Jean El-Cheikh, Maria El Kababri, Léonardo Magro, Fati Hamzy

{"title":"[Acquired severe aplastic anemia in emerging countries: Management from allogeneic hematopoietic cell transplantation indication until post-transplant follow-up SFGM-TC].","authors":"Nabil Yafour, Mohamed Amine Bekadja, Ibtissam El Bejjaj, Jean El-Cheikh, Maria El Kababri, Léonardo Magro, Fati Hamzy","doi":"10.1016/j.bulcan.2024.07.008","DOIUrl":"10.1016/j.bulcan.2024.07.008","url":null,"abstract":"Management of acquired aplastic anemia (AA) in emerging countries depends on the means of prognostic stratification, treatment and logistics available. During the 13th annual harmonization workshop of the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC), a designated working group reviewed the literature in order to elaborate unified guidelines for allogeneic hematopoietic cell transplantation (Allo-HCT) in this disease. In terms of practice, the conclusions are as follows; The use of anti-tymocyte globuline (ATG) is mainly from rabbit and very little from horse. Access to bone marrow graft, total body irradiation, and the international unrelated donor registries is limited, which justifies the use of peripheral blood stem cells, chemotherapy-based conditioning, and related alternative donor. The workshop recommends matched sibling allo-HCT in all patients aged less than 40 years with acquired severe or very severe AA. For patients aged over than 40 years, or who lack an HLA-identical donor, treatment with the combination of cyclosporin, horse ATG, eltrombopag or cyclosporine, eltrombopag is recommended. If horse ATG and eltrombopag are not available, matched sibling allo-HCT may be indicated as first-line therapy in patients aged between 40-60 years, and good performance status. Although, in patients who have failed immunosuppressive treatments and thrombopoietin agonists, and in the absence of HLA-matched donor, a haplo-identical allo-HCT with modified Baltimore conditioning is recommended.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":"S10-S23"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Clinical and transversal competencies of advanced practice nurses (APNs) within a cellular therapy team (SFGM-TC)]. [细胞治疗小组（SFGM-TC）中高级执业护士（APNs）的临床和横向能力]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-09-05 DOI: 10.1016/j.bulcan.2024.06.002

Thomas Jezequel, Rezarta Ajazi Hub, Caroline Bompoint, Céline Chauvel, Elodie Colonnese, Coralie Corbineau, Claire Desmedt, Céline Kicki, Sandra Lomazzi, Anne Sirvent, Solène Evard, Karine Roux, Léonardo Magro, Fabienne Colledani

引用次数: 0

[Selpercatinib in advanced solid tumors with RET fusion, in the absence of therapeutic alternatives]. [在没有其他治疗方案的情况下，Selpercatinib用于晚期实体瘤RET融合治疗]。

Bulletin du cancer Pub Date : 2025-01-01 Epub Date: 2024-12-09 DOI: 10.1016/j.bulcan.2024.11.003

Clara Helal, Stéphane Vignot

引用次数: 0